Composition analysis and oral administered effects on dextran sulfate sodium-induced colitis of galactooligosaccharides bioconverted by Bacillus circulans. (15th October 2021)

• Record Type: Journal Article
• Authors: Park, Hye-Ryung; Eom, Dong Hyun; Kim, Jae Hwan; Shin, Jung-Cheul; Shin, Myoung-Sook; Shin, Kwang-Soon
• Is Part Of: Carbohydrate polymers. Volume 270(2021)
• Publication Date: 2021-10-15
• Subjects: 4′-GL 4′-galactosyllactose -- 5-ASA aminosalicylic acid -- DAI disease activity index -- DP degrees of polymerization -- DSS dextran sulfate sodium -- GOS galactooligosaccharide -- HMO human milk oligosaccharides -- HPLC high performance liquid chromatography -- IL-6 interleukin-6 -- MPO myeloperoxidase -- RID refractive index detector -- MALDI-TOF/MS matrix-assisted laser desorption ionization-time of flight mass spectrometry -- TNF-α tumor necrosis factor-α; Galactooligosaccharides -- Bacillus circulans -- 4′-Galactosyllactose -- Inflammation -- Ulcerative colitis; Polysaccharides -- Periodicals; Polysaccharides -- Periodicals; Polysaccharides -- Périodiques; Electronic journals; 547.78
• DOI: 10.1016/j.carbpol.2021.118389
• Languages: English
• ISSNs: 0144-8617

Abstract

Abstract: Galactooligosaccharides have been known to have many health benefits as prebiotic ingredients. In this study, we examined the anti-inflammatory activity of the galactooligosaccharide, NeoGOS-P70 (Korean commercial product), in a dextran sodium sulfate-induced colitis model. Next, we performed compositional characterization of NeoGOS-P70, which confirmed that it was a 77.4% high-purity GOS products, including a large amount of 4′-galactosyllactose. Further experiments in DSS-induced colitis model showed that oral administration of NeoGOS-P70 could significantly improve DSS-induced colitis symptoms, such as weight loss, reduction in colon shortening, and suppression of inflammatory mediators, including interleukin-6, tumor necrosis factor-α, and myeloperoxidase secretion from colon of ulcerative colitis mice. Histological analysis of mucin expression in colon tissue revealed the protective effects of NeoGOS-P70. These results suggest the potential of the novel GOS, NeoGOS-P70, as an anti-ulcerative colitis agent that could regulate inflammatory responses. Highlights: NeoGOS-P70 is a galactooligosaccharide (GOS) bioconverted by Bacillus circulans . NeoGOS-P70 has a 77.4% GOS content (forms DP2 to DP8), including 4′-galactosyllactose. Oral administration of NeoGOS-P70 improved DSS-induced colitis symptoms. NeoGOS-P70 as an anti-ulcerative colitis agent could regulate inflammatory responses.